🟢 Context Therapeutics is trading 8.26% up in after-hours trading with no clear company-specific catalyst

Context Therapeutics is trading at $0.38 (+8.26%) after-hours, with no major September 14, 2026 company announcement identified.

• The latest release, dated September 9, 2026, announced the first patient dosed in the Phase 1 CT-202 trial.
• The broader market was modestly weaker, so the move does not clearly align with global sentiment.
• Rechecking for delayed news is warranted.